Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
GNAS AS2 methylation status enables mechanism-based categorization of pseudohypoparathyroidism type 1B
Yorihiro Iwasaki, Monica Reyes, Harald Jüppner, Murat Bastepe
Yorihiro Iwasaki, Monica Reyes, Harald Jüppner, Murat Bastepe
View: Text | PDF
Research Article Endocrinology Genetics

GNAS AS2 methylation status enables mechanism-based categorization of pseudohypoparathyroidism type 1B

  • Text
  • PDF
Abstract

Pseudohypoparathyroidism type 1B (PHP1B) results from aberrant genomic imprinting at the GNAS gene. Defining the underlying genetic cause in new patients is challenging because various genetic alterations (e.g., deletions, insertions) within the GNAS genomic region, including the neighboring STX16 gene, can cause PHP1B, and the genotype-epigenotype correlation has not been clearly established. Here, by analyzing patients with PHP1B with a wide variety of genotypes and epigenotypes, we identified a GNAS differentially methylated region (DMR) of distinct diagnostic value. This region, GNAS AS2, was hypomethylated in patients with genetic alterations located centromeric but not telomeric of this DMR. The AS2 methylation status was captured by a single probe of the methylation-sensitive multiplex ligation–dependent probe amplification (MS-MLPA) assay utilized to diagnose PHP1B. In human embryonic stem cells, where NESP55 transcription regulates GNAS methylation status on the maternal allele, AS2 methylation depended on 2 imprinting control regions (STX16-ICR and NESP-ICR) essential for NESP55 transcription. These results suggest that the AS2 methylation status in patients with PHP1B reflects the position at which the genetic alteration affects NESP55 transcription during an early embryonic period. Therefore, AS2 methylation levels can enable mechanistic PHP1B categorization based on genotype-epigenotype correlation and, thus, help identify the underlying molecular defect in patients.

Authors

Yorihiro Iwasaki, Monica Reyes, Harald Jüppner, Murat Bastepe

×

Figure 1

Schematic representation of the GNAS gene locus.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of the GNAS gene locus.
Red and white circles d...
Red and white circles depict methylated and unmethylated DMRs, respectively. Orange boxes indicate imprinting control regions (ICRs) in the STX16 locus (STX16-ICR) or the region surrounding the NESP55 exon within the GNAS locus (NESP-ICR). Arrows indicate the transcriptional direction. A dashed arrow from paternal Gsα exon 1 (ex1) indicates silenced Gsα transcription.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts